Agenus Inc (NAS:AGEN)
$ 14.56 0.99 (7.3%) Market Cap: 305.75 Mil Enterprise Value: 341.77 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Agenus Inc. - Special Call Transcript

Feb 11, 2021 / 06:00PM GMT
Release Date Price: $92.44 (-8.37%)
Jennifer Buell
Agenus Inc. - President & COO

Hi, everyone, and welcome to our first R&D update, which is coined Agenus Insights.

There's never been a more important time in the history of cancer therapy. Technology, partnered with genomic and proteomic insights have accelerated our pace of drug discovery to speeds that have never been seen before. Agenus is at the forefront of this, with more than 15 new discoveries advancing in the clinic in just the past 4 years. A few of those first agents are in route to BLA with filings already underway.

Our anti-PD-1 is delivering differentiated activity compared to commercially available PD-1 antibodies. And 1181, our Fc-engineered anti-CTLA-4, we presented a data update yesterday, and that molecule is producing very exciting results in difficult-to-treat tumors.

Now TIGIT, the topic of our conversation today. It's shaping up as the next breakthrough target in I-O. And only as recently as last year, anti-CTLA-4 and anti-PD-1 were the only validated immunotherapy combinations for patients with cancer. Today, this third pathway

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot